Benzinga | Feb 24, 2021 05:19AM EST

SVB Leerink Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $210

SVB Leerink analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $213 to $210.